Agitation in Alzheimer's disease
Central neuropathic pain in multiple sclerosis
Levodopa induced dyskinesia in Parkinson's disease
Speech & Swallowing in ALS"
European partnership would just be the standard upfront license fee, royalties on European sales to Avanir and maybe milestone payments. Nothing to do with R&D. Even AVNR is not paying for the Levodopa induced dyskinesia in Parkinson's study, or speech and swallowing in ALS or autism.
Avanir will continue to completely fund R&D for neuropathic pain and will hopefully cut bait sooner rather than later on agitation in dementia, but probably they'll waste more and more time and money on it because Avanir mistakenly thinks it makes for good advertising for the stock shares.